eliquis apixaban

  • Site Map
  • Privacy Policy
  • Legal Notice
  • Pharmacovigilance Notice
  • Contact Us

Home / Site map
  • Site Map
  • Privacy Policy
  • Legal Notice
  • Pharmacovigilance Notice
  • Contact Us

Site Map

Home

  • Home

Atrial Fibrillation

  • What is atrial fibrillation?
  • Causes of AF
  • Complications associated with AF
  • Symptoms of stroke
  • ELIQUIS (apixaban)
  • How to take apixaban
  • Possible side effects with apixaban
  • Patient alert card
  • Patient information booklet
  • Further sources of information and support

DVT or PE

  • What is VTE, DVT and PE?
  • Causes of VTE
  • Signs and symptoms
  • Complications
  • Can a VTE recur?
  • Prevention of VTE events
  • ELIQUIS (apixaban)
  • How to take apixaban
  • Possible side effects
  • Patient alert card
  • Patient information booklet
  • Further sources of information and support

Following Surgery

  • What is VTE?
  • Causes of VTE
  • Preventing VTE
  • ELIQUIS (apixaban)
  • How to take apixaban
  • Possible side effects
  • Patient alert card
  • Patient Information Booklet
  • Further sources of information and support

You may contact our EU Data Protection Officer at EUDPO@BMS.com to exercise any data privacy rights that you may have, as well as to raise any concerns or questions in relation to the handling of your personal data by Bristol-Myers Squibb Company.

  • Home
  • Site Map
  • Privacy Policy
  • Legal Notice
  • Pharmacovigilance Notice
  • Contact Us

  • Home
  • Site Map
  • Privacy Policy
  • Legal Notice
  • Pharmacovigilance Notice
  • Contact Us

© 2020 Bristol-Myers Squibb Pharmaceuticals Limited

All corporate names and logos of BMS and/or of its products are trademarks of Bristol-Myers Squibb Company and are protected by national and international intellectual and industrial property laws. All rights reserved over the content of this website.

Your use of this website is subject to the Legal Notice, the Privacy and Cookie Policy, the Pharmacovigilance Notice and the applicable laws and regulations.

432UK1700565-01
Date of preparation: June 2017

You Are Leaving This Site

This link takes you to a website of Bristol-Myers Squibb Group or Pfizer Group that may have a different purpose, contents which might not be appropriate for all kinds of public as per the applicable laws, or may have different terms and conditions. The Alliance (Bristol-Myers Squibb Group and Pfizer Group) recommends that you check whether it is suitable for you as per its intended audience and the applicable laws and regulations before accessing it.

Would you like to leave this site?

Continue Stay on this site

You are about to leave this Website.

This link takes you to a third party website (outside of the Bristol-Myers Squibb Group and Pfizer Group). Bristol-Myers Squibb and Pfizer has no control over the content or management of third party websites nor can it be held responsible or liable for such content or management. Please make sure the contents therein are suitable for you as per its intended audience and the applicable laws and regulations. It is recommended that you carefully read the legal notice and cookies and privacy policy of third party websites before accessing these sites.

If you wish to continue, click ‘Continue’, otherwise click ‘Stay on this site’.

Continue Stay on this site

You are about to leave this Website.

This link takes you to a third party website (outside of the Bristol-Myers Squibb Group and Pfizer Group). Bristol-Myers Squibb and Pfizer has no control over the content or management of third party websites nor can it be held responsible or liable for such content or management. Please make sure the contents therein are suitable for you as per its intended audience and the applicable laws and regulations. It is recommended that you carefully read the legal notice and cookies and privacy policy of third party websites before accessing these sites.

If you wish to continue, click ‘Continue’, otherwise click ‘Stay on this site’.

Continue Stay on this site